Comparison of Two Nucleic Acid Amplification Tests (NAATs) and Two Antigen Tests for Detection of SARS-CoV-2 from Upper Respiratory Specimens

AbstractThe RT-qPCR in respiratory specimens is the gold standard for diagnosing acute COVID-19 infections. However, this test takes considerable time before test results become available, thereby delaying patients from being diagnosed, treated, and isolated immediately. Rapid antigen tests could overcome this problem. In the first study, clinical performances of five rapid antigen tests were compared to RT-qPCR in upper respiratory specimens from 40 patients with positive and 40 with negative RTq-PCR results. In the second study, the rapid antigen test with one of the best test characteristics (Romed) was evaluated in a large prospective collection of upper respiratory specimens from 900 different COVID-19-suspected patients (300 emergency room patients, 300 nursing home patients, and 300 health care workers). Test specificities ranged from 87.5 to 100.0%, and test sensitivities from 55.0 to 80.0%. The clinical specificity of the Romed test was 99.8% (95% CI 98.9–100). Overall clinical sensitivity in the study population was 73.3% (95% CI 67.9–78.2), whereas sensitivity in the different patient groups varied from 65.3 to 86.7%. Sensitivity was 83.0 to 86.7% in patients with short duration of symptoms. In a population with a COVID-19 prevalence of 1%, the negative predictive value in all patients was 99.7%. There is a large variability in diagnostic performance between rapid antigen tests. The Romed rapid antigen test showed a good clinical performance in patients with high viral loads (RT-qPCR cycle threshold ≤30), which makes this antigen test suitable for rapid identification of COVID-19-infected health care workers and patients.

Download Full-text

Is it time to use nucleic acid amplification tests for identification of persons with sexually transmitted infections?

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2020.09.1168 ◽

2020 ◽

Vol 101 ◽

pp. 446

Author(s):

L. Tobin ◽

L. Guerra ◽

L. Ahouanvoeke ◽

J.A.G. Carpio ◽

D. Irambona ◽

...

Keyword(s):

Nucleic Acid ◽

Sexually Transmitted Infections ◽

Nucleic Acid Amplification ◽

Nucleic Acid Amplification Tests ◽

Sexually Transmitted ◽

Identification Of Persons

Download Full-text

Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing

Open Forum Infectious Diseases ◽

10.1093/ofid/ofaa466 ◽

2020 ◽

Vol 7 (11) ◽

Author(s):

Gwynngelle A Borillo ◽

Ron M Kagan ◽

Russell E Baumann ◽

Boris M Fainstein ◽

Lamela Umaru ◽

...

Keyword(s):

Real Time ◽

False Negative ◽

False Negative Rate ◽

Nucleic Acid Amplification ◽

Rt Pcr ◽

Pooled Testing ◽

Negative Results ◽

Single Positive ◽

Upper Respiratory ◽

Respiratory Specimens

Abstract Background Nucleic acid amplification testing is a critical tool for addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Specimen pooling can increase throughput and conserve testing resources but requires validation to ensure that reduced sensitivity does not increase the false-negative rate. We evaluated the performance of a real-time reverse transcription polymerase chain reaction (RT-PCR) test authorized by the US Food and Drug Administration (FDA) for emergency use for pooled testing of upper respiratory specimens. Methods Positive specimens were selected from 3 prevalence groups, 1%–3%, >3%–6%, and >6%–10%. Positive percent agreement (PPA) was assessed by pooling single-positive specimens with 3 negative specimens; performance was assessed using Passing-Bablok regression. Additionally, we assessed the distributions of RT-PCR cycle threshold (Ct) values for 3091 positive specimens. Results PPA was 100% for the 101 pooled specimens. There was a linear relationship between Ct values for pooled and single-tested specimens (r = 0.96–0.99; slope ≈ 1). The mean pooled Ct shifts at 40 cycles were 2.38 and 1.90, respectively, for the N1 and N3 targets. The median Cts for 3091 positive specimens were 25.9 (N1) and 24.7 (N3). The percentage of positive specimens with Cts between 40 and the shifted Ct was 1.42% (N1) and 0.0% (N3). Conclusions Pooled and individual testing of specimens positive for SARS-CoV-2 demonstrated 100% agreement, which demonstrates the viability of pooled specimens for SARS-COV-2 testing using a dual-target RT-PCR system. Pooled specimen testing can help increase testing capacity for SARS-CoV-2 with a low risk of false-negative results.

Download Full-text

Is it time to move to nucleic acid amplification tests screening for pharyngeal and rectal gonorrhoea in men who have sex with men to improve gonorrhoea control?

Sexual Health ◽

10.1071/sh10134 ◽

2011 ◽

Vol 8 (1) ◽

pp. 9 ◽

Cited By ~ 20

Author(s):

Christopher K. Fairley ◽

Marcus Y. Chen ◽

Catriona S. Bradshaw ◽

Sepehr N. Tabrizi

Keyword(s):

Nucleic Acid ◽

Antimicrobial Resistance ◽

Sexual Health ◽

Nucleic Acid Amplification ◽

Nucleic Acid Amplification Tests ◽

Health Clinics ◽

Sex With Men ◽

Sexual Health Clinics

The use of nucleic acid amplification tests (NAAT), as well as or in preference to culture for non-genital sites is now recommended both in Australia and overseas because of their greater sensitivity and improved specificity. A survey of 22 Australian sexual health clinics who each year test over 14 500 men who have sex with men (MSM) show that culture remains the predominate method for detecting gonorrhoea at pharyngeal (64%) and rectal (73%) sites. This editorial discusses the potential disadvantages of using culture over NAAT in relation to optimal gonorrhoea control among MSM and advocates that significantly improved control would be achieved by moving to NAAT with the proviso that culture samples are taken wherever possible on NAAT-positive samples and from clients with urethritis to ensure continued surveillance for antimicrobial resistance.

Download Full-text